Related Experiment Video
Updated: Jun 15, 2026
08:46
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Pharmacogenetics in oncology: a promising field
D Houtsma1, H J Guchelaar, H Gelderblom
1Department of Clinical Oncology, PO Box 9600, 2300 RC Leiden, Leiden University Medical Center, The Netherlands.
Current Pharmaceutical Design
|March 9, 2010
Summary
Pharmacogenetics enables personalized cancer therapy by analyzing germline genetics to tailor treatments, improving efficacy and reducing toxicity. Further research is needed to determine optimal implementation of genetic screening in oncology.
Area of Science:
- Oncology
- Pharmacogenetics
- Genetics
Background:
- Pharmacogenetics is a rapidly advancing field in oncology.
- Individualizing cancer therapy based on germline genetic test results can enhance treatment efficacy and reduce toxicity.
- Identifying non-responders allows for alternative therapy selection or dose adjustments.
Purpose of the Study:
- To review extensively studied pharmacogenetic pathways in oncology.
- To highlight the impact of genetic variations on drug metabolism and efficacy.
- To discuss the current challenges and future directions for implementing pharmacogenetic screening in clinical oncology.
Main Methods:
- Review of existing literature on pharmacogenetic pathways in cancer treatment.
- Analysis of genetic variations affecting drug response, including 5FU, irinotecan, platinum, and tamoxifen.
- Discussion of the implications of genetic testing for personalized oncology.
Main Results:
- Variations in DPYD, TYMS, and MTHFR genes are linked to increased 5FU toxicity.
- UGT1A and ABCB1 gene variations affect irinotecan metabolism.
- Genetic factors influence DNA repair capacity for platinum drugs and CYP2D6 activity for tamoxifen.
Conclusions:
- Pharmacogenetic studies show promising results for personalized cancer therapy.
- The optimal timing and method for pretreatment genetic screening in oncology remain unclear.
- Future research should focus on prospective studies evaluating patient outcomes, cost-effectiveness, and predictive models for genetic screening.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...